United States Copper Index Fund vs Revvity Inc — how do they compare? United States Copper Index Fund trades at $40.24 (market cap $708.28M), while Revvity Inc trades at $153.89 (market cap $16.98B). The key difference: Revvity Inc is far larger — about 24× United States Copper Index Fund's market cap, and Revvity Inc pays a 0.18% dividend while United States Copper Index Fund pays none. Which is the better fit depends on your goals — on Pluang, investors hold United States Copper Index Fund for 48 Days and Revvity Inc for 12 Days on average.
| CPER | RVTY | |
|---|---|---|
Market Cap | $708.28M | $16.98B |
Volume | 339,046 | 1,456,900 |
Sector | Commodities - Metals/Agriculture | Health |
52-Week High | $41.43 | $157.36 |
52-Week Low | $30.27 | $82.26 |
Typical Hold Time | 48 Days | 12 Days |
Enterprise Value | — | $19.30B |
Dividend Yield | — | 0.18% |
Signals from Pluang's Aura AI — not financial advice
CPER is trading at $39.81, down 0.55% on the day, with a neutral technical signal overall. The stock shows bullish momentum in moving averages but neutral oscillators, with key support at $39 and resistance at $40. Recent news highlights strong copper demand driven by AI infrastructure needs, though copper prices have shown volatility with recent declines.
The outlook for CPER is mixed, with positive copper demand fundamentals balanced by near-term price volatility. Investment opportunities center on exposure to copper's role in AI and electrification trends, while risks include commodity price swings and potential supply chain disruptions. Wall Street sentiment appears cautiously optimistic given copper's strategic importance.
RVTY trades at $153.60, up 0.2% today and near its 52-week high of $158.28 (Defense World, 2026-10-01). The stock shows a bullish technical trend with strong moving average signals and has beaten earnings estimates for three consecutive quarters. Recent developments include the launch of a CE-IVDR-certified T1D screening kit in Europe (Business Wire, 2026-09-24) and the acquisition of Human Cell Design to expand metabolic disease research tools (Business Wire, 2026-09-09).
The outlook is positive, supported by earnings momentum, strategic acquisitions, and analyst optimism. However, the stock trades at a premium valuation with a P/E of 73.15, and near-term risks include margin pressures in China and rich valuation limiting upside beyond consensus targets. Revenue stability but slight profit margin compression in 2026 warrants monitoring.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
CPER is a commodity ETF that tracks the price of copper futures via the SummerHaven Copper Index. It provides direct exposure to the 'red metal' using a rules-based strategy to select futures contracts, making it a key tool for hedging or betting on industrial growth and electrification.
Read more on CPER →Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.
Read more on RVTY →